Literature DB >> 33648632

Self-blinding citizen science to explore psychedelic microdosing.

Balázs Szigeti1, Laura Kartner1, Allan Blemings1, Fernando Rosas1,2,3, Amanda Feilding4, David J Nutt1,5, Robin L Carhart-Harris1, David Erritzoe1,5.   

Abstract

Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a 'self-blinding' citizen science initiative, where participants were given online instructions on how to incorporate placebo control into their microdosing routine without clinical supervision. The study was completed by 191 participants, making it the largest placebo-controlled trial on psychedelics to-date. All psychological outcomes improved significantly from baseline to after the 4 weeks long dose period for the microdose group; however, the placebo group also improved and no significant between-groups differences were observed. Acute (emotional state, drug intensity, mood, energy, and creativity) and post-acute (anxiety) scales showed small, but significant microdose vs. placebo differences; however, these results can be explained by participants breaking blind. The findings suggest that anecdotal benefits of microdosing can be explained by the placebo effect.
© 2021, Szigeti et al.

Entities:  

Keywords:  citizen science; expectations; human; medicine; microdosing; neuroscience; placebo; psychedelics; self-blinding

Mesh:

Substances:

Year:  2021        PMID: 33648632      PMCID: PMC7925122          DOI: 10.7554/eLife.62878

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  37 in total

1.  The role of non-specific factors in treatment outcome of psychotherapy studies.

Authors:  I Chatoor; J Krupnick
Journal:  Eur Child Adolesc Psychiatry       Date:  2001       Impact factor: 4.785

2.  The Satisfaction With Life Scale.

Authors:  E Diener; R A Emmons; R J Larsen; S Griffin
Journal:  J Pers Assess       Date:  1985-02

3.  Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.

Authors:  Nadia R P W Hutten; Natasha L Mason; Patrick C Dolder; Eef L Theunissen; Friederike Holze; Matthias E Liechti; Amanda Feilding; Johannes G Ramaekers; Kim P C Kuypers
Journal:  Eur Neuropsychopharmacol       Date:  2020-10-17       Impact factor: 4.600

4.  Fractionating human intelligence.

Authors:  Adam Hampshire; Roger R Highfield; Beth L Parkin; Adrian M Owen
Journal:  Neuron       Date:  2012-12-20       Impact factor: 17.173

5.  How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine.

Authors:  J G Rabkin; J S Markowitz; J Stewart; P McGrath; W Harrison; F M Quitkin; D F Klein
Journal:  Psychiatry Res       Date:  1986-09       Impact factor: 3.222

6.  Measuring ideas of persecution and social reference: the Green et al. Paranoid Thought Scales (GPTS).

Authors:  C E L Green; D Freeman; E Kuipers; P Bebbington; D Fowler; G Dunn; P A Garety
Journal:  Psychol Med       Date:  2007-10-01       Impact factor: 7.723

7.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

Review 8.  Placebo Effect in the Treatment of Depression and Anxiety.

Authors:  Irving Kirsch
Journal:  Front Psychiatry       Date:  2019-06-13       Impact factor: 4.157

9.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

10.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Authors:  Leor Roseman; David J Nutt; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

View more
  19 in total

Review 1.  Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.

Authors:  Jacob S Aday; Boris D Heifets; Steven D Pratscher; Ellen Bradley; Raymond Rosen; Joshua D Woolley
Journal:  Psychopharmacology (Berl)       Date:  2022-04-01       Impact factor: 4.530

2.  Ibogaine microdosing in a patient with bipolar depression: a case report.

Authors:  Maria Helha Fernandes-Nascimento; Karine Viana-Ferreira; Bruno Daniel Rasmussen Chaves; André Brooking Negrão; Yuan-Pang Wang
Journal:  Braz J Psychiatry       Date:  2022-07-27

3.  Psychedelic microdosing hits a rough patch in clinical trials.

Authors:  Benjamin Plackett
Journal:  Nature       Date:  2022-09       Impact factor: 69.504

4.  Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Authors:  Joseph M Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Zach Walsh
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

Review 5.  Molecular targets of psychedelic-induced plasticity.

Authors:  Alaina M Jaster; Mario de la Fuente Revenga; Javier González-Maeso
Journal:  J Neurochem       Date:  2021-11-15       Impact factor: 5.546

6.  Dosing Psychedelics and MDMA.

Authors:  Matthias E Liechti; Friederike Holze
Journal:  Curr Top Behav Neurosci       Date:  2022

7.  The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Authors:  P Mallaroni; N L Mason; F R J Vinckenbosch; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2022-04-30       Impact factor: 4.415

8.  Asking questions of psychedelic microdosing.

Authors:  Lindsay P Cameron
Journal:  Elife       Date:  2021-03-02       Impact factor: 8.140

9.  MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.

Authors:  Robin J Murphy; Rachael L Sumner; William Evans; David Menkes; Ingo Lambrecht; Rhys Ponton; Frederick Sundram; Nicholas Hoeh; Sanya Ram; Lisa Reynolds; Suresh Muthukumaraswamy
Journal:  Trials       Date:  2021-04-23       Impact factor: 2.279

Review 10.  1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Authors:  Sylvana Vilca-Melendez; Malin V Uthaug; Julian L Griffin
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.